bioMérieux S.A.'s latest marketcap:
As of 07/04/2025, bioMérieux S.A.'s market capitalization has reached $16.52 B. According to our data, bioMérieux S.A. is the 1277th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 16.52 B |
| Revenue (ttm) | 4.69 B |
| Net Income (ttm) | 508.9 M |
| Shares Out | 117.93 M |
| EPS (ttm) | 4.29 |
| Forward PE | 26.25 |
| Ex-Dividend Date | 06/09/2025 |
| Earnings Date | 09/04/2025 |
bioMérieux S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | €16.52 B | 13.26% | 1277 |
| 12/31/2024 | €12.21 B | 2.78% | 1402 |
| 12/29/2023 | €11.88 B | 2.52% | 1288 |
| 12/30/2022 | €11.59 B | -21.58% | 1270 |
| 12/31/2021 | €14.78 B | 8.25% | 1171 |
| 12/31/2020 | €13.65 B | 45.7% | 1031 |
| 12/31/2019 | €9.37 B | 38.4% | 1280 |
| 12/31/2018 | €6.77 B | -23.39% | 1436 |
| 12/29/2017 | €8.84 B | 57.88% | 1225 |
| 12/30/2016 | €5.6 B | 29.15% | 1667 |
Company Profile
About bioMérieux S.A.
bioMérieux S.A. is a global leader in in vitro diagnostic solutions, specializing in the detection and management of infectious diseases. The company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Key Products & Solutions
- CHROMID RANGE – Chromogen culture media for bacterial identification.
- RAPIDEC CARBA NP – Biochemical test for carbapenemase-producing bacteria detection.
- BACT/ALERT VIRTUO & 3D – Blood sample culture systems.
- BIOFIRE & BIOFIRE SPOTFIRE – Multiplex PCR and point-of-care testing systems.
- VITEK MS & VITEK 2 – Mass spectrometry and automated antimicrobial susceptibility testing.
- API RANGE – Standardized ID strips for microbial identification.
- ETEST Gradient – Method for antibiotic susceptibility testing.
- BIOMERIEUX EPISEQ CS – Whole genome sequencing for epidemiologic monitoring.
- VIDASB·R·A·H·M·S PCT™ – Sepsis biomarker testing.
- Biomérieux Vision Suite – Diagnostic decision-support software.
- ARGENE Monoplex PCR – Targeted pathogen detection.
- NUCLISENS & EMAG – Molecular biology automation and extraction systems.
- GENE-UP & VERIFLOW – Food industry microorganism detection.
Industries Served
The company provides solutions for:
- Clinical and hospital laboratories
- Physicians and blood banks
- Veterinary diagnostics
- Industrial control laboratories
Company Background
Founded in 1963 as B-D Mérieux, bioMérieux S.A. is headquartered in Marcy-l'Étoile, France. It operates as a subsidiary of Institut Mérieux SA.
Frequently Asked Questions
-
What is bioMérieux S.A.'s (EPA-BIM) current market cap?As of 07/04/2025, bioMérieux S.A. (including the parent company, if applicable) has an estimated market capitalization of $16.52 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does bioMérieux S.A. (EPA-BIM) rank globally by market cap?bioMérieux S.A. global market capitalization ranking is approximately 1277 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.